Swog Cancer Research Network

This large, completed study compared two different drug combinations for men newly diagnosed with prostate cancer that had spread to other parts of the body. Over 1,300 participants received standard hormone therapy plus either an experimental drug (TAK-700) or an established dru…

This study tested which of two drug combinations worked better to control advanced colorectal cancer that had a specific genetic feature called HER2 amplification. The trial involved 240 patients whose cancer had spread and could not be removed by surgery. One group received two …

This large study tested whether taking the drug everolimus for about a year could help prevent kidney cancer from returning after patients had surgery to remove their tumor. It involved over 1500 patients who were considered at high risk of their cancer coming back. Patients were…

This large, completed study aimed to find the better add-on treatment for newly diagnosed follicular lymphoma, a type of blood cancer. It compared standard chemotherapy (CHOP) combined with one of two different antibody drugs: rituximab or a radioactive antibody called tositumoma…

This Phase 2 trial tested whether the antibody drug isatuximab could help control AL amyloidosis in patients whose disease had returned or didn't respond to prior treatments. The study enrolled 43 adults with confirmed organ damage from this rare protein disorder. Participants re…

This large, completed Phase 3 trial tested whether adding a third chemotherapy drug (nab-paclitaxel) to the standard two-drug treatment (gemcitabine and cisplatin) works better for people newly diagnosed with advanced cancers of the bile ducts, gallbladder, or liver. The study in…

This study tested if adding a targeted drug called ramucirumab to standard chemotherapy (carboplatin and paclitaxel) works better for people with advanced thymic cancer that cannot be removed by surgery. It involved 21 patients who were randomly assigned to receive either the sta…